Literature DB >> 28994196

Demographics, management and treatment outcomes of benign and malignant retroperitoneal tumors in Japan.

Naohiro Fujimoto1, Tatsuhiko Kubo2, Masanori Hisaoka3, Kazuma Udo4, Akira Yokomizo5, Tadamasa Shibuya6, Hironobu Wakeda7, Kiyoaki Nishihara8, Ryosuke Moriya1, Keiko Iwakuma1.   

Abstract

OBJECTIVES: To show the demographics, type of treatment and clinical outcomes of patients with retroperitoneal tumors in Japan.
METHODS: We carried out a retrospective analysis of patients with retroperitoneal tumors treated between 2000 and 2012 at 12 university hospitals in Japan. Histology was re-evaluated using the 2013 World Health Organization classification.
RESULTS: A total of 167 patients were included in the analysis. The number of diagnosed patients increased over the 12-year study period. Liposarcoma and schwannoma were the most common histological types among intermediate/malignant and benign tumors, respectively. The intermediate/malignant tumors were larger and were more frequently found in older people. Surgical resection was the primary treatment for 151 patients. The median survival duration for patients with malignant tumors was 91 months, and was significantly shorter than that for patients with benign and intermediate tumors (P < 0.01). R2 resection was associated with significantly shorter survival than R0/R1 resection for malignant tumors (P < 0.01), but not for intermediate. Grossly complete resection of the recurrent tumors improved survival.
CONCLUSION: The number of patients diagnosed with retroperitoneal tumors increased over time. R2 resection of primary tumors was found to be associated with poor prognosis in malignant tumors, but not in intermediate tumors. Complete surgical resection of recurrent tumors was associated with a better oncological outcome.
© 2017 The Authors. International Journal of Urology published by John Wiley & Sons Australia, Ltd on behalf of the Japanese Urological Association.

Entities:  

Keywords:  Japan; demographics; retroperitoneal tumor; soft-tissue tumor; treatment outcome

Mesh:

Year:  2017        PMID: 28994196     DOI: 10.1111/iju.13469

Source DB:  PubMed          Journal:  Int J Urol        ISSN: 0919-8172            Impact factor:   3.369


  7 in total

1.  Surgical management of retroperitoneal schwannoma complicated with severe hydronephrosis: A case report.

Authors:  Liandong Zhang; Ming Gao; Tongdian Zhang; Tie Chong; Ziming Wang; Wenpin Liu; Hecheng Li
Journal:  Medicine (Baltimore)       Date:  2018-09       Impact factor: 1.889

2.  Retroperitoneal space-occupying lesion with displacement of the inferior vena cava.

Authors:  Stefan Niebisch; Holger Staab; Sebastian Ullrich; Karl-Titus Hoffmann; Osama Sabri; René Thieme; Katrin Schierle; Christian Wittekind; Ines Gockel
Journal:  Int J Surg Case Rep       Date:  2019-03-30

3.  Clinical Characteristics and Treatment Strategy of Retroperitoneal Schwannoma Adjacent to Important Abdominal Vessels: Three Case Reports and Literature Review.

Authors:  Qi Wu; Bingqiang Liu; Jun Lu; Hong Chang
Journal:  Front Surg       Date:  2021-01-14

4.  Survival outcomes of surgery for retroperitoneal sarcomas: A systematic review and meta-analysis.

Authors:  Qiang Guo; Jichun Zhao; Xiaojiong Du; Bin Huang
Journal:  PLoS One       Date:  2022-07-28       Impact factor: 3.752

5.  Retroperitoneal Hydropic Leiomyoma Mimicking an Ovarian Cyst.

Authors:  Pei-Hsuan Lai; Dah-Ching Ding
Journal:  Case Rep Obstet Gynecol       Date:  2022-08-04

6.  Evaluation of clinical application of multi-slice computerized tomography in primary retroperitoneal tumors.

Authors:  Yuanchun Feng; Wei Zhang; Chenghua Luo
Journal:  J Clin Lab Anal       Date:  2019-12-27       Impact factor: 2.352

7.  Rare retroperitoneal conditions that mimic uterine myoma.

Authors:  Răzvan Mihai Popovici; Alexandru Cărăuleanu; Claudia Florida Costea; Irina Daniela Florea; Dragoş Viorel Scripcariu; Raluca Anamaria Mogoş; Ali Cheaito; Adina Elena Tănase; Raluca Maria Haba; Mihaela Grigore
Journal:  Rom J Morphol Embryol       Date:  2020       Impact factor: 1.033

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.